Impact of metformin therapy in patients with polycystic ovarian syndrome
Abstract
OBJECTIVE: To determine the effect of metformin therapy in achieving menstrual regularity, pregnancy, reducing obesity and hyperinsulinemia in patients with polycystic ovarian syndrome (PCOS).
DESIGN: Interventional, quasi-experimental study.
PLACE AND DURATION OF STUDY: Civil Hospital, Karachi from January 2002 to December 2003.
PATIENTS AND METHODS: Thirty patients with PCOS diagnosed on clinical symptoms, ultrasound examination and hormonal assays were selected. All patients either had raised serum fasting insulin levels or fasting blood sugar/serum fasting insulin ratio of < 4:5. Patients were then given treatment with Metformin 500 mg TID and continued for six months. The patients were called back for follow-up on monthly basis and clinical and bio-chemical variables were recorded on a proforma at 3 months and 6 months of initiating metformin treatment. The chi-square test was done and p-value determined to assess the outcome.
RESULTS: Significant effect of metformin therapy was observed at 3 months follow-up visit, 5 (16.7%) women achieved pregnancy while 20 (66.6%) women had a regular menstrual cycle (p = 0.001), and a significant reduction in weight (67.4 vs. 65.4, p = 0.001) and hyperinsulinemia (FBS: FI = 3.34 vs. 6.63, p = 0.001) was noted. After 6 months follow-up visit, 25 women were examined. Of these, 7 (28%) achieved pregnancy while 16 (64%) had regular menstrual cycle (p = 0.001) and a significant reduction in weight and hyperinsulinemia (p = 0.001).…
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 25 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.